CLTA: A Promising Protein for Vaccines and Therapies (G1211)

Target Name: CLTA

NCBI ID: G1211

CLTA

CLTA: A Promising Protein for Vaccines and Therapies

CLTA, or Clathrin, Light Polypeptide (Lca), is a protein that is expressed in various tissues throughout the body. It is a member of the tyrosine kinase family and is involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. CLTA has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, CLTA has become a focus of interest for researchers and pharmaceutical companies as a potential drug target or biomarker.

CLTA was first identified in the late 1980s as a potential vaccine candidate for smallpox. This was due to the fact that CLTA was found to be able to elicit an effective immune response in animal models of smallpox. Since then, further studies have demonstrated that CLTA is a strong candidate for a vaccine against smallpox, as well as against other diseases such as cancer.

One of the reasons why CLTA is considered a promising vaccine candidate is its ability to induce long-term memory responses in the immune system. This is important for ensuring that the immune system has a strong memory of the pathogen and is able to rapidly recognize and respond to any future infections. Studies have shown that CLTA is able to induce long-term memory responses in animal models of smallpox, as well as against other viruses and bacteria.

Another potential advantage of CLTA as a vaccine is its ability to be administered in a different form than traditional vaccines, such as an adjuvant. This is important because traditional vaccines, such as those for smallpox, require a high dose of the vaccine to be effective . Adjuvants, on the other hand, are substances that enhance the immune response to the vaccine. CLTA has been shown to be a highly effective adjuvant in animal models of smallpox and has the potential to be used in smallpox vaccines in humans.

In addition to its potential as a vaccine, CLTA has also been shown to be a potential drug target. Studies have shown that CLTA is able to inhibit the activity of a protein called PD-L1, which is a protein that helps to protect cancer cells from the immune system. This suggests that CLTA could be used as a therapy for cancer by inhibiting the activity of PD-L1.

Another potential application of CLTA as a drug target is its ability to modulate the immune response. Studies have shown that CLTA is able to alter the balance of regulatory and autocrine T cells in the immune system, which could have implications for the development of autoimmune diseases . Additionally, CLTA has also been shown to have anti-inflammatory effects, which could make it a potential therapy for diseases that are characterized by chronic inflammation.

In conclusion, CLTA is a protein that has shown great potential as a drug target and biomarker. Its ability to induce long-term memory responses in the immune system and its potential as an adjuvant for smallpox vaccines make it an attractive candidate for further research. Additionally, its ability to modulate the immune response and its potential anti-inflammatory effects make it a potential therapy for a variety of diseases. As research continues to advance, it is likely that we will learn even more about the potential applications of CLTA.

Protein Name: Clathrin Light Chain A

Functions: Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Acts as component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge (PubMed:15858577, PubMed:21297582)

The "CLTA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLTA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets